<DOC>
	<DOCNO>NCT00483275</DOCNO>
	<brief_summary>Objective study evaluate effect multimodal therapy basis current guideline fall prevention consist 12-months intervention Alfacalcidol calcium , patient education mobility program group patient 65 year age old impaired renal function comparison group receive usual care .</brief_summary>
	<brief_title>Fall Prevention Alfacalcidol Training</brief_title>
	<detailed_description>The risk fall increase age . An impaired renal function additional risk factor . Guidelines systematic review suggest , multimodal intervention likely control risk . This study evaluate , patient high risk fall benefit multimodal intervention simple feasible enough transfer general practice . Participants randomize either intervention group control group receive usual care . The multimodal intervention consist : - medication : Participants receive 1µg Alfacalcidol 500mg Calcium daily - mobility program : strength , balance gait training twice week one hour - patient education : single meeting teach lesson risk factor fall mode fall prevention follow evaluation individual fall risk correspond recommendation reduce</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Alfacalcidol</mesh_term>
	<mesh_term>Hydroxycholecalciferols</mesh_term>
	<criteria>Men woman 65 year age old Personal history least one movementrelated , nonsyncopal fall , either within past year OR early additional finding increase fall risk screen examination . Creatinineclearance 30 60 ml/min equivalent moderately impaired kidney function ( stage 3 ) accord classification Kidney Disease Outcomes Quality Initiative ( K/DOQI ) National Kidney Foundation ( NKF ) . Immobility inability go participate training course History fracture stroke provide event occur last 3 month Presence physical mental disorder lead setup plan setup statutory care Severe dementia Severe disorder speech comprehension Disease rule participation intervention period would deteriorate result type intervention ( e.g . absorptive hypercalciuria , nephrocalcinosis , calcium contain renal calculus hypophosphataemia ) Hypersensitivity ( allergy ) Alfacalcidol , groundnut , groundnut oil Soya VitaminD hypersensitivity intoxication Simultaneous intake vitamin D derivative . Participation clinical trial , still ongoing complete less 3 month prior date intend inclusion Substitution 500 mg calcium per day Planned medical therapy period intervention require longterm suspension intervention . Presence hypercapnia 2.6mmol/l , calcium x phosphate product 3.7 ( mmol/l ) 2 alkalosis venous bloodpH read 7.44 ( milkalkalisyndrome , Burnett syndrome ) Hypercalcaemia ( e.g . result hyperparathyroidism , overdose vitamin D , paraneoplastic syndrome , osseous metastasis , sarcoidosis , Boeck´s disease , osteoporosis induced immobilisation ) hypermagnesemia accord normative value engage laboratory Hereditary fructose intolerance Commitment institution</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Accidental Falls</keyword>
	<keyword>Accident Prevention</keyword>
	<keyword>Patient Education</keyword>
	<keyword>Exercise Training</keyword>
	<keyword>Alfacalcidol</keyword>
</DOC>